posted on 2019-11-27, 14:40authored byFelicitas Vernen, David J. Craik, Nicole Lawrence, Sónia Troeira Henriques
Tachyplesin-I (TI) is a host defense peptide from the
horseshoe
crab Tachypleus tridentatus that has outstanding
potential as an anticancer therapeutic lead. Backbone cyclized TI
(cTI) has similar anticancer properties to TI but has higher stability
and lower hemolytic activity. We designed and synthesized cTI analogues
to further improve anticancer potential and investigated structure–activity
relationships based on peptide–membrane interactions, cellular
uptake, and anticancer activity. The membrane-binding affinity and
cytotoxic activity of cTI were found to be highly dependent on peptide
hydrophobicity and charge. We describe two analogues with increased
selectivity toward melanoma cells and one analogue with the ability
to enter cells with high efficacy and low toxicity. Overall, the structure–activity
relationship study shows that cTI can be developed as a membrane-active
antimelanoma lead, or be employed as a cell penetrating peptide scaffold
that can target and enter cells without damaging their integrity.